Non-Surgical Nasal Polyp Procedure
Advanced Nasal Polyp Treatment Option
Now there is an advanced, in-office treatment option that reduces polyps and nasal congestion and obstruction: SINUVA® (mometasone furoate) Sinus Implant.2 SINUVA® Sinus Implant is FDA-approved for adult patients who have had ethmoid sinus surgery and experience recurrent nasal polyps.
Reduce Nasal Polyps without Surgery
We offer a non-surgical procedure for patients who suffer from repeat nasal polyps with SINUVA® (mometasone furoate) Sinus Implant. SINUVA® is proven to reduce polyps and nasal congestion and obstruction.1
What is SINUVA® Sinus Implant?
SINUVA® is an innovative treatment for nasal polyps that doesn’t require surgery. It is a drug-releasing, non-permanent implant that is placed during a routine office visit. First, your doctor will numb your nose and sinuses with topical and/or local anesthesia. Then SINUVA® is placed in the sinus cavity through the nasal opening.
How SINUVA® Works
SINUVA® Sinus Implant opens in the sinus cavity and delivers anti-inflammatory medicine in the ethmoid sinus for up to 90 days. It can be removed earlier at your doctor’s discretion.
Benefits and Risks of SINUVA® at Day 903,4
- Significantly reduces nasal congestion and obstruction
- Significantly improves impaired sense of smell
- Significantly reduces the percentage of patients eligible for revision sinus surgery
The most common adverse reactions observed in a clinical trial were bronchitis, upper respiratory or middle ear infection, headache, light-headedness, asthma and nose bleed.
Contact Us today for more SINUVA® information.
1Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016, 6 Suppl 1:S22-S209.
2SINUVA Prescribing Information, Intersect ENT. December 2017
3Data on file, Intersect ENT, Inc. RESOLVE II CSR R-28017 Rev 3.0 February 2017
4Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol.2018;8:471–81.
SINUVA® Sinus Implant is a steroid-releasing (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
If you have a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, do not use SINUVA. Hypersensitivity reactions, including rash, itch, and swelling have been reported with use of steroids. If steroid effects such as Cushing Syndrome and adrenal suppression appear, consult your healthcare professional.
SINUVA is made from bioabsorbable polymers designed to soften over time. As the implant softens and polyps decrease, the implant may be expelled out of the nose on its own or with actions such as sneezing or forceful nose blowing. The implant can be removed 90 days after placement or earlier at the physician’s discretion. Repeat administration of SINUVA has not been studied. As with other endoscopic sinus procedures, there are risks associated with the insertion or removal of SINUVA. SINUVA should be inserted by physicians trained in otolaryngology. Discuss risks related to insertion or removal of SINUVA with your healthcare professional.
Your healthcare professional will monitor the nasal tissue adjacent to the SINUVA Sinus Implant for any signs of bleeding, irritation, infection, or perforation. SINUVA should not be used in patients with nasal ulcers or trauma. The most common adverse reactions observed in clinical studies were bronchitis, upper respiratory or middle ear infection, headache, lightheadedness, asthma, and nose bleed. If you experience excessive nasal bleeding, worsening symptoms of infections, viral eye infections, or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, immediately contact a healthcare professional.
Close monitoring is recommended if you have a change of vision or a history of increased intraocular pressure, glaucoma and/or cataracts. You may report side effects to your physician or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Intersect ENT at 1-866-531-6004. RX Only. For important risk and use information about SINUVA, please see Full Prescribing Information or visit www.SINUVA.com.
MPM-00763 Rev A